About Mydecine Innovations Group, Inc. 
Mydecine Innovations Group, Inc.
Pharmaceuticals & Biotechnology
Mydecine Innovations Group Inc. is a Canada-based biopharma and life sciences company. The Company is focused on the research, development and acceptance of alternative nature-sourced medicine. Its portfolio of companies includes Mydecine Health Sciences (MHS), Mindleap Health Inc. (Mindleap) and NeuroPharm, Inc (NPI). MHS is focused on developing fungtional mushroom products and psychedelic medicines for the consumer and professional healthcare market. NPI is a veterans-focused healthcare company that is developing pharmaceutical and natural health products for mental wellness in vulnerable populations, including veterans, emergency medical services (EMS) personnel and other high-risk constituencies. NPI is developing psilocybin-assisted psychotherapy to treat chronic post-traumatic stress disorder (PTSD). Mindleap offers a digital health platform that enables people connect with mental health specialists, who can help them to develop habits for a healthy mind.
Company Coordinates 
Company Details
Suite 810 - 789 West Pender Street , VANCOUVER BC : V6C 1H2
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
No Data
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
Pharmaceuticals & Biotechnology
CAD 0 Million ()
NA (Loss Making)
NA
0.00%
-0.46
6.72%
-0.02






